Important Safety Information for Clobex® Products
Clobex® (clobetasol propionate), 0.05%, is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe plaque psoriasis.
Clobetasol propionate has been shown to suppress the HPA axis at the lowest doses tested.
Adverse events associated with use of Clobex® (clobetasol propionate, 0.05%) Spray, Lotion and/or Shampoo include burning/stinging, skin dryness, irritation, erythema, hyperpigmentation, telangiectasia and skin atrophy. In clinical trials, these side effects were typically mild in nature and transient.
Clobex® Spray, Lotion and Shampoo, 0.05%, are not recommended for use on anyone younger than 18 years of age. Clobetasol propionate, 0.05%, should not be used on the face, groin or axillae, and the total dosage should not exceed 50 g (50 mL or 1.75 fl oz of Shampoo or Lotion, or 59 mL or 2 fl oz of Spray) per week. Patients should use Clobex® Shampoo, 0.05%, Clobex® Spray, 0.05%, or Clobex® Lotion, 0.05%, only for the minimum period necessary to achieve desired results, and treatment beyond 2 weeks in psoriasis should be weighed against the potential risk for HPA axis suppression. Pregnancy Category C.
Click here for full Prescribing Information for Clobex® Spray.
Click here for full Prescribing Information for Clobex® Shampoo.
Click here for full Prescribing Information for Clobex® Lotion.
Important Safety Information for Vectical® Ointment
Vectical® (calcitriol) Ointment 3 mcg/g is a topical treatment for mild to moderate plaque psoriasis in adults 18 years and older.
The most frequent adverse events (≥3%) reported in clinical trials were lab test abnormality, urine abnormality, psoriasis, hypercalciuria, pruritus and skin discomfort. Vectical® should be used with caution in patients with known or suspected disturbances in calcium homeostasis, who are taking calcium or Vitamin D supplements or who are on diuretics. If aberrations in parameters of calcium metabolism occur, discontinue use until these normalize. Caution patients to avoid excessive exposure to natural or artificial sunlight after applying the ointment. Avoid contact with eyes, lips and face. Limit use to 200 grams per week.
Click here for full Prescribing Information for Vectical® Ointment.
Legal | Privacy | Site Map | Contact Us | Galderma Laboratories, L.P.
© 2011 Galderma Laboratories, L.P. United States. All Rights Reserved. GALDERMA, Vectical and Clobex are registered trademarks. All other trademarks are the property of their respective owners.
This site intended for US audiences only.
Galderma Laboratories, L.P. | 14501 N. Freeway | Fort Worth, TX 76177
Full Prescribing Information:
Clobex® (clobetasol propionate) Spray, 0.05%
Clobex® Shampoo, 0.05%
Clobex® Lotion, 0.05%
Vectical® (calcitriol) Ointment 3 mcg/g